by Peter Ciszewski | Aug 2, 2021
Brenton Mar, MD, PhD, Senior Medical Director at Blueprint Medicines, gives an overview of systemic mastocytosis (SM) and advanced SM. SM is a rare, hematologic disorder most often caused by a mutation in the KIT D816V gene. The disorder is characterized by...
by Peter Ciszewski | Jul 30, 2021
Daniel Auclair, MD, Chief Scientific Officer of the Multiple Myeloma Research Foundation (MMRF), talks about what physicians should know about multiple myeloma. Multiple myeloma is a rare blood cancer associated with uncontrolled growth of plasma cells....
by Peter Ciszewski | Jul 29, 2021
Sharon Hrynkow, MD, Chief Scientific Officer and Senior VP for Medical Affairs, Cyclo Therapeutics, discusses the mechanism of action of hydroxypropyl betacyclodextrin (Trappsol® Cyclo™) which is currently being evaluated as a treatment of Niemann-Pick...
by Peter Ciszewski | Jul 28, 2021
Daniel DeAngelo, MD, PhD, Chief, Division of Leukemia, Dana-Farber Cancer Institute, discusses the mechanism of action of avapritinib, a kinase inhibitor recently approved for the treatment of advanced systemic mastocytosis (SM). SM is a rare, hematologic...
by Peter Ciszewski | Jul 27, 2021
Thanos Zomas, MD, from Takeda Oncology, discusses follow-up data from the ECHELON-1 study presented at EHA 2021 and ASCO 2021. The ECHELON-1 study was an open-label, randomized, phase 3 study comparing brentuximab vedotin (Adcetris; A) in combination with...
